Immunovia AB (publ) announced it is realigning its Swedish operations with its strategic priorities to drive R&D productivity and focus on the US commercialization of the IMMray(TM) PanCan-d test. Immunovia has initiated a consultation process with relevant Swedish unions to create the best possible transition for the affected employees. The Company will provide an update once the consultation process is concluded.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 SEK | -2.08% |
|
-5.77% | -9.71% |
Jul. 02 | Immunovia Offers an Update on Its New Lab in Research Triangle Park, USA | CI |
May. 21 | Immunovia Seeks SEK70 Million from Proposed Rights Offering | MT |
1st Jan change | Capi. | |
---|---|---|
-9.71% | 6.88M | |
-56.07% | 2.17B | |
+19.09% | 1.88B | |
-12.63% | 1.45B | |
+29.99% | 1.32B | |
+8.32% | 853M | |
-30.60% | 799M | |
-36.50% | 726M | |
+29.48% | 622M | |
-29.02% | 594M |
- Stock Market
- Equities
- IMMNOV Stock
- News Immunovia AB
- Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test